Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 13,738 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: Facioscapulohumeral Muscular Dystrophy
Interventions: FSHD-specific functional rating scale, Electrical Impedance Myography; Diagnostic Test · Device
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 5 more

Conditions: Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome, Myeloid Leukemia Associated With Down Syndrome, Myeloproliferative Neoplasm
Interventions: Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine, Daunorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Thioguanine; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 91 Days to 3 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 169
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 131 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ivonescimab Injection, Pembrolizumab Injection; Biological
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 97
States / cities: Chandler, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 86 more

Conditions: Chronic Hepatitis C
Interventions: SCV-07; Drug
Lead sponsor: SciClone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 16
States / cities: Anaheim, California • Los Angeles, California • Palm Springs, California + 12 more

Conditions: Chronic Migraine in Children
Interventions: Eptinezumab, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 22
States / cities: New Haven, Connecticut • Stamford, Connecticut • Washington D.C., District of Columbia + 19 more

Conditions: Cervical Degenerative Disc Disease
Interventions: Cervical Artificial Disc (Advent™ Cervical Disc), Hallmark™ Anterior Cervical Plate System; Device
Lead sponsor: Orthofix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 13
States / cities: Sacramento, California • Boulder, Colorado • Tampa, Florida + 10 more

Conditions: Asthma
Interventions: Apieron Insight eNO monitor; Device
Lead sponsor: Apieron; Industry
Eligibility: 12 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 12
States / cities: Mission Viejo, California • San Jose, California • Glastonbury, Connecticut + 9 more

Conditions: Aortic Stenosis
Interventions: ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, Edwards SAPIEN 3 TAVR System, ACURATE Prime™ Transfemoral TAVR System XL; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: Not listed
Enrollment: 1,948 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 69
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 58 more

Conditions: Pancreatic Cancer
Interventions: Mitomycin-C; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions: Experimental Observation, Observation per Standard of Care, Adjuvant Treatment per Standard of Care, Circulating Tumor DNA test (ctDNA test); Other · Radiation · Diagnostic Test
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more

Conditions: Diabetes, Pre-diabetes, Obesity
Interventions: Metformin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 10 Years to 79 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Epilepsy
Interventions: Progesterone Lozenges, Matched Placebo Lozenges; Biological · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 13 Years to 45 Years · Female only
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 14
States / cities: Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 8 more

Conditions: Diabetes, Obesity, Pre-Diabetes, Metabolic Syndrome
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 12 Years to 50 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Small Cell Lung Cancer, Small Cell Lung Carcinoma
Interventions: ABT-263; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 14
States / cities: Peoria, Arizona • Phoenix, Arizona • Los Angeles, California + 10 more

Conditions: Systemic Lupus Erythematosus
Interventions: Memantine, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Spinal Cord Injury, Paraplegia, Tetraplegia
Interventions: Exoskeletal-assisted walking (ReWalk, Ekso); Device
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 3
States / cities: Baltimore, Maryland • West Orange, New Jersey • The Bronx, New York

Conditions: Pharmacokinetics of Repaglinide, Pharmacokinetics of Caffeine, Healthy Subjects
Interventions: Isavuconazole, Repaglinide, Caffeine; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
Interventions: AMXI-5001:Dose Escalation Phase I, AMXI-5001:Dose Expansion Phase II; Drug
Lead sponsor: AtlasMedx, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Nashville, Tennessee + 1 more

Conditions: Utilization, Health Care, Engagement, Patient, No-Show Patients
Interventions: Home visit; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: IPMN, IPMN, Pancreatic
Interventions: Sulindac 400 MG, Placebo; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 21 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more

Conditions: Narcolepsy
Interventions: ADX-N05, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Redwood City, California + 23 more

Conditions: Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Laboratory Biomarker Analysis, Placebo, Tivantinib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 20
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 14 more

Conditions: Graves' Disease
Interventions: IMVT-1402; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 89
States / cities: Phoenix, Arizona • Tucson, Arizona • Concord, California + 75 more

Conditions: Stress Urinary Incontinence
Interventions: tension-free vaginal tape, TVT-SECUR device; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 21 Years and older · Female only
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Durham, North Carolina + 4 more

Search by objective public record fields.

Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

Advent™ Cervical Disc Versus ACDF for Treatment of One Level Degenerative Disc Disease (IDE Study)

Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO)

ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement

Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene

Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)

Metformin at the Cellular Level and Dosing for Diabetes Mellitus (DM)

Progesterone vs Placebo Therapy for Women With Epilepsy

A Study of the Function of Hormones Present In Taste Buds

A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies

Memantine in Systemic Lupus Erythematosus

Exoskeletal-assisted Walking to Improve Mobility, Bowel Function and Cardio-Metabolic Profiles in Persons With SCI

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Home Visits for Patients at Risk for Appointment No-shows

The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

Tivantinib in Treating Patients With Metastatic Prostate Cancer

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

Study Comparing TVT With TVT-SECUR for the Treatment of Stress Urinary Incontinence